Streetbeat News

Stock Prices

GFF

Griffon (NYSE:GFF) reported Q3 2024 adjusted EPS of $1.24, missing the analyst estimate of $1.31. Sales were $647.8 million, also below the $688.94 million estimate and down 5.21% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am

EHTH

eHealth has projected its FY24 revenue to be between $470 million and $495 million, surpassing the estimated $466.574 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am

EYPT

EyePoint Pharmaceuticals reported Q2 2024 GAAP EPS of $(0.58), missing the $(0.53) estimate. Sales were $9.477M, also missing the $9.593M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am

EHTH

eHealth (NASDAQ:EHTH) reported Q2 2024 GAAP EPS of $(1.33), missing the $(1.14) estimate by 16.67%. However, sales of $65.856M beat the $55.024M estimate by 19.69%, despite a 1.37% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:32 am

APLT

Applied Therapeutics announced that its cash and cash equivalents of $122.2 million are expected to fund the business into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:32 am

NYAX

Nayax (NASDAQ: NYAX) reported Q2 2024 GAAP EPS of $(0.08), missing the $(0.01) estimate by 730%. However, sales of $78.087M beat the $77.457M estimate by 0.81%, marking a 39.05% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:32 am

KRNT

Kornit Digital (NASDAQ:KRNT) reported Q2 2024 adjusted EPS of $0.02, beating the $(0.01) estimate, but sales of $48.621M missed the $49.322M estimate. EPS improved significantly from $(0.15) last year, while sales decreased by 13.48% from $56.199M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:32 am

APLT

Applied Therapeutics reported a Q2 2024 GAAP EPS of $(0.13), beating the estimate of $(0.15). Sales were $144.000K, which may not be comparable to the $2.500M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:31 am

CRL

Charles River Laboratories International shares are trading lower after the company reported Q2 financial results and cut its FY24 adjusted guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:29 am

ACRS

Aclaris Therapeutics reported its Q2 2024 financial results, with a GAAP EPS of $(0.15), beating the estimate of $(0.20). The company's sales were $2.766 million, surpassing the expected $1.818 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:28 am